Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

Northwestern Medicine scientists have uncovered new details about the genetic structure of ovarian cancer stem cells, ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

A US bankruptcy judge has rejected Johnson & Johnson's $10 billion proposal to end thousands of lawsuits alleging that its ...

Strengthened the cash balance to provide runway into 2027, allowing Allarity to accelerate stenoparib's clinical development, ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

US Bankruptcy Judge Christopher Lopez on Monday dismissed the bankruptcy of a small J&J unit called Red River Talc following ...